Novo bets big on diabetes meds

Share this article:

Novo Nordisk is investing $3.65 billion in needle-free diabetes treatments. Reuters reports that the drug maker is looking to develop pills that can replace injected insulins, and tells the news service it has dedicated 500 employees to developing six candidates.

The company projects that it could have the new medication market-ready in 10 years.
Share this article:
You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.